| アブストラクト | BACKGROUND: Valbenazine is indicated for tardive dyskinesia, a movement disorder associated with long-term antipsychotic treatment. This study aimed to clarify changes in real-world antipsychotic prescribing patterns before and after valbenazine initiation. METHODS: This retrospective observational study used real-world claims data of patients with a valbenazine prescription extracted from the Medical Data Vision (MDV) and JMDC databases. The pre-valbenazine period was 183 days before the initiation date, defined as the first valbenazine prescription. The main outcome was antipsychotic drug use by dose, type, and drug class within the pre-valbenazine period and after the valbenazine initiation date. Data in the pre-valbenazine period were compared between the latest date (latest date of antipsychotic prescription before the initiation date) and the earliest date (date of the first antipsychotic prescription within the pre-valbenazine period). RESULTS: The primary analysis included 225 and 141 patients from MDV and JMDC, respectively. During the pre-valbenazine period, the mean difference in chlorpromazine-equivalent doses of antipsychotic medication was +12.4 mg/day and +1.2 mg/day for patients in MDV and JMDC, respectively; there were no clear differences in the mean dose or number and types of antipsychotic drugs between dates. From the latest date to 90 days after the initiation date, the mean difference in antipsychotic dose was -38.3 mg/day and -57.6 mg/day in MDV and JMDC, respectively ( approximately 10% decrease). CONCLUSIONS: Real-world data clarified antipsychotic dosing around valbenazine initiation. Within the 6-month period before valbenazine initiation, antipsychotic doses were stable. Subsequently, minimal changes in antipsychotic dosing were observed after starting valbenazine treatment. |
|---|
| ジャーナル名 | Journal of clinical psychopharmacology |
|---|
| Pubmed追加日 | 2026/11/2 |
|---|
| 投稿者 | Gouda, Maki; Kakinoki, Bunpei; Asai, Hidetoshi; Ashizawa, Koji; Takeuchi, Hiroyoshi |
|---|
| 組織名 | Development and Medical Affairs Division, Tanabe Pharma Corporation, Tokyo,;Japan.;Pharmaceutical Business Development Department, Takumi Information Technology;Inc., Tokyo, Japan.;Department of Psychiatry, Chiba University Graduate School of Medicine, Chiba, |
|---|
| Pubmed リンク | https://www.ncbi.nlm.nih.gov/pubmed/42969062/ |
|---|
